Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 12/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140583 | 0.80 | SLC6A2 (0.49) | TDO2HTR1ASLC6A2SLC6A3NMT1 | |
| SCHEMBL385942 | 0.79 | GPR119 (0.57) | — | |
| SCHEMBL4723322 | 0.77 | GPR119 (0.45) | HTR7 | |
| SCHEMBL27747809 | 0.73 | GPR119 (0.39) | EGFR | |
| SCHEMBL83203 | 0.72 | SLC6A2 (0.62) | HTR1ASLC6A2SLC6A3NMT1 | |
| Hydrochloric Acid SCHEMBL69817 | 0.70 | HTR1A (0.60) | TDO2HTR1ASLC6A2SLC6A3NMT1 | |
| SCHEMBL30775284 | 0.70 | HRH4 (0.46) | — | |
| SCHEMBL5049760 | 0.70 | GPR119 (0.43) | TDO2HTR1ASLC6A2SLC6A3EGFR | |
| SCHEMBL5046883 | 0.69 | GPR119 (0.39) | EGFR | |
| SCHEMBL5049506 | 0.68 | FLT3 (0.43) | TDO2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |